WO2005030723A1 - Pyridylacetylenes for use as radiotracers and imaging agents - Google Patents
Pyridylacetylenes for use as radiotracers and imaging agents Download PDFInfo
- Publication number
- WO2005030723A1 WO2005030723A1 PCT/EP2004/010743 EP2004010743W WO2005030723A1 WO 2005030723 A1 WO2005030723 A1 WO 2005030723A1 EP 2004010743 W EP2004010743 W EP 2004010743W WO 2005030723 A1 WO2005030723 A1 WO 2005030723A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- methyl
- free base
- acid addition
- Prior art date
Links
- 0 Cc1cccc(C#CC(CCC2)=CC2=NO*)n1 Chemical compound Cc1cccc(C#CC(CCC2)=CC2=NO*)n1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to novel pyridylacetylene derivatives, their preparation, their use as radiotracers/markers and compositions containing them.
- R is CH 3) (CH 2 ) n l, (CH 2 ) n Br or (CH 2 ) n F, n being 1 , 2, 3 or 4
- R is 11 CH 3 , ( 3 H) 3 C, (CH 2 ) n 123 l (CH 2 ) n 76 Br or (CH 2 ) n 18 F, n being 1 ,2, 3 or 4
- the compounds can exist as pure stereoisomers or mixtures thereof.
- the invention provides a process for the production of the compounds of formula I and their salts, comprising the steps of
- R a is respectively 11 CH 3 or ( 3 H) 3 C, reacting the compound of formula II
- Rb is respectively (CH 2 ) n 18 F, (CH 2 ) n 123 l or (CH 2 ) n 76 Br, reacting a compound of formula III
- n is as defined above and X is OTs or OMs, with respectively 18r F-c ⁇ >, 123
- the reactions can be effected according to known methods, for example as described in the Examples.
- Acid addition salts may be produced from the free bases in known manner, and vice-versa.
- agents of the invention exhibit valuable properties as histopathological labeling agents, imaging agents and/or biomarkers, hereinafter "markers", for the selective labeling of the metabotropic glutamate receptor subtype 5 (mGlu ⁇ receptor).
- agents of the invention are useful as markers for labeling the central and peripheral mGlu ⁇ receptors in vitro or in vivo (see Example 5-7).
- the agents of the invention are therefore useful, for instance, for determining the levels of receptor occupancy of a drug acting at the mGlu5 receptor, or diagnostic purposes for diseases resulting from an imbalance or dysfunction of mGlu ⁇ receptors, and for monitoring the effectiveness of pharmacotherapies of such diseases.
- the present invention provides an agent of the invention for use as a marker for neuroimaging.
- the present invention provides a composition for labeling brain and peripheral nervous system structures involving mGlu ⁇ receptors in vivo and in vitro comprising an agent of the invention.
- the present invention provides a method for labeling brain and peripheral nervous system structures involving mGlu ⁇ receptors in vitro or in vivo, which comprises contacting brain tissue with an agent of the invention.
- the method of the invention may comprise a further step aimed at determining whether the agent of the invention labeled the target structure.
- Said further step may be effected by observing the target structure using positron emission tomography (PET) or single photon emission computed tomography (SPECT), or any device allowing detection of radioactive radiations.
- PET positron emission tomography
- SPECT single photon emission computed tomography
- 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone 0-[ 11 C-methyl]-oxime is synthesized by reacting [ 11 C]-Mel with the sodium salt of 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime (1mg) in dry DMF (400 ⁇ l). [ 11 C]-Mel is introduced via a slow stream of helium and when addition is completed the reaction mixture is heated to 120°C for 10 min.
- Product purification is accomplished by reversed phase HPLC using a C-18 ⁇ -Bondapak column (7.8x300mm) and a mobile phase consisting of CH 3 CN/0.1% H 3 P0 4 (70/30) at a flow rate of 5 ml/min.
- the retention time of the desired product is between 6 and 7 min.
- 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone 0-[ 11 C-methyl]-oxime is formulated in a solution containing polysorbatum (2%), ethanol (10%) and saline (0.9%).
- LogD 2.5 (determined using the classical shake-flask method).
- the title compound can be prepared by reacting 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2- enone oxime with [ 3 H]-Mel (0.5 equivalent) in the presence of K 2 C0 3 in DMF at 100°C for 180 min, followed by a purification by reversed phase chromatography.
- the sodium salt of the 3-(6-methyl-pyridin-2-ylethynyl)-cycIohex-2-enone oxime (2mg) is reacted in dry DMF (400 ⁇ l) with [ 18 F]-2-fluoro-ethyltosylate (obtained from ethyleneditosylate and [ 18 F]-KF-Kryptofix complex) at 100°C for 10min.
- the reaction mixture is purified through a tC-18 Sep-Pak cartridge, and the fractions containing the desired product are further purified by a semi-preparative reversed phase HPLC using a C18 Bondclone column (300x7.8 mm) and a mobile phase consisting of CH 3 CN/0.01 M H 3 P0 4 (70/30) at a flow rate of 4 ml/min.
- the fraction containing the product (retention time between 12 and 13 min) is passed through a tC-18 Sep-Pak cartridge and eluted with 1 ml of ethanol. This ethanolic solution is buffered with 0.15M phosphate buffer to give after sterile filtration an isotonic and injectable solution.
- the product is formulated in analogy to 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone 0-(2- [18F-fluoro]-ethyl)-oxime (example 3).
- the animals are sacrificed 30 min post-injection.
- Organ or brain regions such as hippocampus, striatum, cortex and cerebellum are removed and measured in a gamma- counter.
- the tissue distribution is expressed as percentage of injected dose per gram wet tissue (% ID/g organ).
- Example 7 Results of the brain distribution study with 3-(6-methyl-pyridin-2- ylethvnyl)-cvclohex-2-enone O-f 11 C-methy ⁇ -oxime
- K1, K2, K3 are individual values for control animals.
- B1, B2, B3 are individual values for animals co-injected with 2-methyl-6-((3-methoxyphenyl)ethynyl)-pyridine.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2539469A CA2539469C (en) | 2003-09-26 | 2004-09-24 | Pyridylacetylenes for use as radiotracers and imaging agents |
AU2004275971A AU2004275971B2 (en) | 2003-09-26 | 2004-09-24 | Pyridylacetylenes for use as radiotracers and imaging agents |
BRPI0414732-4A BRPI0414732A (en) | 2003-09-26 | 2004-09-24 | pyridylacetylenes for use as radiotracers and imaging agents |
JP2006527359A JP4965255B2 (en) | 2003-09-26 | 2004-09-24 | Pyridylacetylenes for use as radioactive tracers and contrast agents |
ES04765586T ES2400713T3 (en) | 2003-09-26 | 2004-09-24 | Pyridyl-acetylenes for use as radio-trackers and imaging agents |
EP04765586A EP1670762B1 (en) | 2003-09-26 | 2004-09-24 | Pyridylacetylenes for use as radiotracers and imaging agents |
PL04765586T PL1670762T3 (en) | 2003-09-26 | 2004-09-24 | Pyridylacetylenes for use as radiotracers and imaging agents |
US10/573,162 US8674110B2 (en) | 2003-09-26 | 2004-09-24 | Pyridylacetylenes for use as radiotracers and imaging agents |
MXPA06003424A MXPA06003424A (en) | 2003-09-26 | 2004-09-24 | Pyridylacetylenes for use as radiotracers and imaging agents. |
US14/162,885 US20140142318A1 (en) | 2003-09-26 | 2014-01-24 | Pyridylacetylenes for use as radiotracers and imaging agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0322612.3A GB0322612D0 (en) | 2003-09-26 | 2003-09-26 | Organic compounds |
GB0322612.3 | 2003-09-26 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/573,162 A-371-Of-International US8674110B2 (en) | 2003-09-26 | 2004-09-24 | Pyridylacetylenes for use as radiotracers and imaging agents |
US14/162,885 Continuation US20140142318A1 (en) | 2003-09-26 | 2014-01-24 | Pyridylacetylenes for use as radiotracers and imaging agents |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005030723A1 true WO2005030723A1 (en) | 2005-04-07 |
Family
ID=29286926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/010743 WO2005030723A1 (en) | 2003-09-26 | 2004-09-24 | Pyridylacetylenes for use as radiotracers and imaging agents |
Country Status (13)
Country | Link |
---|---|
US (2) | US8674110B2 (en) |
EP (1) | EP1670762B1 (en) |
JP (1) | JP4965255B2 (en) |
CN (1) | CN100430380C (en) |
AU (2) | AU2004275971B2 (en) |
BR (1) | BRPI0414732A (en) |
CA (1) | CA2539469C (en) |
ES (1) | ES2400713T3 (en) |
GB (1) | GB0322612D0 (en) |
MX (1) | MXPA06003424A (en) |
PL (1) | PL1670762T3 (en) |
PT (1) | PT1670762E (en) |
WO (1) | WO2005030723A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010084050A2 (en) | 2009-01-13 | 2010-07-29 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
EP2305652A2 (en) | 2005-12-08 | 2011-04-06 | Novartis AG | Trisubstituted quinazolinone derivatives as vanilloid antagonists |
WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
WO2012004400A1 (en) * | 2010-07-09 | 2012-01-12 | Recordati Ireland Limited | Novel spiroheterocyclic compounds as mglu5 antagonists |
WO2012164473A1 (en) | 2011-05-27 | 2012-12-06 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
WO2013164790A1 (en) | 2012-05-03 | 2013-11-07 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001016121A1 (en) * | 1999-08-31 | 2001-03-08 | Merck & Co., Inc. | Heterocyclic compounds and methods of use thereof |
WO2004038374A2 (en) * | 2002-10-24 | 2004-05-06 | Merck & Co., Inc. | Alkyne derivatives as tracers for metabotropic glutamate receptor binding |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6843979B2 (en) | 1999-04-26 | 2005-01-18 | Emory University | 4-haloethenylphenyl tropane:serotonin transporter imaging agents |
AU767726B2 (en) | 1999-04-30 | 2003-11-20 | Pfizer Products Inc. | Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease |
WO2001001621A2 (en) * | 1999-06-30 | 2001-01-04 | Sun Microsystems, Inc. | Customizing web content based on network conditions |
GB0103045D0 (en) * | 2001-02-07 | 2001-03-21 | Novartis Ag | Organic Compounds |
JP4070431B2 (en) | 2001-07-10 | 2008-04-02 | ジーイー・ヘルスケア・リミテッド | Iodine-added neuroprobe for mapping monoamine reuptake sites |
-
2003
- 2003-09-26 GB GBGB0322612.3A patent/GB0322612D0/en not_active Ceased
-
2004
- 2004-09-24 PL PL04765586T patent/PL1670762T3/en unknown
- 2004-09-24 BR BRPI0414732-4A patent/BRPI0414732A/en not_active IP Right Cessation
- 2004-09-24 CN CNB2004800273094A patent/CN100430380C/en not_active Expired - Fee Related
- 2004-09-24 ES ES04765586T patent/ES2400713T3/en active Active
- 2004-09-24 EP EP04765586A patent/EP1670762B1/en not_active Not-in-force
- 2004-09-24 JP JP2006527359A patent/JP4965255B2/en not_active Expired - Fee Related
- 2004-09-24 MX MXPA06003424A patent/MXPA06003424A/en active IP Right Grant
- 2004-09-24 WO PCT/EP2004/010743 patent/WO2005030723A1/en active Application Filing
- 2004-09-24 PT PT47655865T patent/PT1670762E/en unknown
- 2004-09-24 CA CA2539469A patent/CA2539469C/en not_active Expired - Fee Related
- 2004-09-24 AU AU2004275971A patent/AU2004275971B2/en not_active Ceased
- 2004-09-24 US US10/573,162 patent/US8674110B2/en not_active Expired - Fee Related
-
2008
- 2008-12-23 AU AU2008261192A patent/AU2008261192B2/en not_active Ceased
-
2014
- 2014-01-24 US US14/162,885 patent/US20140142318A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001016121A1 (en) * | 1999-08-31 | 2001-03-08 | Merck & Co., Inc. | Heterocyclic compounds and methods of use thereof |
WO2004038374A2 (en) * | 2002-10-24 | 2004-05-06 | Merck & Co., Inc. | Alkyne derivatives as tracers for metabotropic glutamate receptor binding |
Non-Patent Citations (1)
Title |
---|
GASPARINI, F. ET AL.: "[3H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5.", BIOORG. MED. CHEM. LETT., vol. 12, 2002, pages 407 - 409, XP002313757 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2305652A2 (en) | 2005-12-08 | 2011-04-06 | Novartis AG | Trisubstituted quinazolinone derivatives as vanilloid antagonists |
WO2010084050A2 (en) | 2009-01-13 | 2010-07-29 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
WO2012004400A1 (en) * | 2010-07-09 | 2012-01-12 | Recordati Ireland Limited | Novel spiroheterocyclic compounds as mglu5 antagonists |
US8580962B2 (en) | 2010-07-09 | 2013-11-12 | Recordati Ireland Ltd. | Spiroheterocyclic compounds as mGlu5 antagonists |
AU2011275696B2 (en) * | 2010-07-09 | 2016-02-11 | Recordati Ireland Limited | Novel spiroheterocyclic compounds as mGlu5 antagonists |
EA023020B1 (en) * | 2010-07-09 | 2016-04-29 | Рекордати Айерленд Лимитед | SPIROHETEROCYCLIC COMPOUNDS AND USE THEREOF AS mGlu5 ANTAGONISTS |
KR101862626B1 (en) | 2010-07-09 | 2018-05-31 | 레코르다티 아일랜드 리미티드 | Novel spiroheterocyclic compounds as mglu5 antagonists |
WO2012164473A1 (en) | 2011-05-27 | 2012-12-06 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
WO2013164790A1 (en) | 2012-05-03 | 2013-11-07 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
Also Published As
Publication number | Publication date |
---|---|
CN1856468A (en) | 2006-11-01 |
CA2539469C (en) | 2012-06-19 |
ES2400713T3 (en) | 2013-04-11 |
PL1670762T3 (en) | 2013-05-31 |
PT1670762E (en) | 2013-02-07 |
GB0322612D0 (en) | 2003-10-29 |
EP1670762B1 (en) | 2012-12-05 |
JP4965255B2 (en) | 2012-07-04 |
MXPA06003424A (en) | 2006-06-20 |
AU2008261192A1 (en) | 2009-01-22 |
AU2004275971A1 (en) | 2005-04-07 |
US20090010838A1 (en) | 2009-01-08 |
BRPI0414732A (en) | 2006-11-21 |
EP1670762A1 (en) | 2006-06-21 |
AU2008261192B2 (en) | 2011-08-04 |
US8674110B2 (en) | 2014-03-18 |
CN100430380C (en) | 2008-11-05 |
JP2007506698A (en) | 2007-03-22 |
AU2004275971B2 (en) | 2008-10-02 |
US20140142318A1 (en) | 2014-05-22 |
CA2539469A1 (en) | 2005-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008261192B2 (en) | Pyridylacetylenes for use as radiotracers and imaging agents | |
JP2950616B2 (en) | Triterpene derivative | |
Hintermann et al. | ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies | |
DK158351B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF SUBSTITUTED 4-PHENYLALKYLIMIDAZOLD DERIVATIVES OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS. | |
JPS60112793A (en) | 6-vinyl-furo-(3,4-c)-pyridine derivative, manufacture and medicinal composition | |
Martin-Encinas et al. | Synthesis of novel hybrid quinolino [4, 3-b][1, 5] naphthyridines and quinolino [4, 3-b][1, 5] naphthyridin-6 (5H)-one derivatives and biological evaluation as topoisomerase I inhibitors and antiproliferatives | |
DE2501468A1 (en) | HETEROAROYLHETEROCYCLEN | |
DE4330959A1 (en) | New benzimidazole derivatives, processes for their preparation and their pharmaceutical use | |
CA1246077A (en) | Vinyl carboxylic acid derivatives, their production and use | |
JPH03209348A (en) | Production of eneyne derivative | |
EP0114573B1 (en) | Imidazo(1,5-a)pyridine derivatives | |
EP0080154B1 (en) | N-substituted 2-pyridyl indoles, process for their preparation, pharmaceutical compositions containing them, and their therapeutical use | |
JPS5928521B2 (en) | Nematicidal composition | |
US8158782B2 (en) | Biomolecule labeling reactants based on azacycloalkanes and conjugates derived thereof | |
JPS6163671A (en) | 2,3-dihydrobenzofuran-5-sulfonamide derivative and hypotensive diuretic | |
EP0313288B1 (en) | Imidazole derivatives, process for their preparation and their use as alpha 2-adreno-receptor antagonists | |
CN113307758B (en) | P2X7 receptor targeting probe precursor labeled by medical radioactive isotope | |
JP2007506698A5 (en) | ||
EP0966440B1 (en) | Method of production and method of separation of 2,4'-dipyridyl derivatives and methods of production of benzoxazepine derivatives and salts thereof | |
Mátyus et al. | Novel pyridazino [4, 5-b][1, 5] oxazepines and-thiazepines as 5-HT1A receptor ligands | |
SMITH et al. | Convenient Syntheses of 1, 2, 3, 4-Tetrahydroquinoxalines | |
DE60215837T2 (en) | 2-AMINO-6- (2,4,5-SUBSTITUTED-PHENYL) -PYRIDINES FOR USE AS STICK OXIDE SYNTHASE INHIBITORS | |
KR950003922B1 (en) | Process for preparation of 1,-4 dihydropyridine derivatives | |
JPH0395138A (en) | Optical resolution of 3-methylheptanoic acid | |
US4992563A (en) | Benzopyran intermediates for use in manufacturing thromboxane A2 antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480027309.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004765586 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004275971 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2539469 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/003424 Country of ref document: MX Ref document number: 1019/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006527359 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004275971 Country of ref document: AU Date of ref document: 20040924 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004275971 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10573162 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004765586 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0414732 Country of ref document: BR |